NCT03202758 - Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 29, 2017

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG

Durvalumab, Tremelimumab and ,FOLFOX

"Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX"

Trial Locations (5)

21000

Centre Georges François Leclerc, Dijon

Unknown

CHRU Besançon, Besançon

CHU Nantes, Nantes

Hôpital Europeen Georges Pompidou, Paris

Hôpital Saint Antoine, Paris